The regulator had asked Sarepta Therapeutics to stop all the expeditions of his therapy, elessys, after three patients had died of hepatic insufficiency after taking it or similar treatment.
The regulator had asked Sarepta Therapeutics to stop all the expeditions of his therapy, elessys, after three patients had died of hepatic insufficiency after taking it or similar treatment.
